Compare · BXRX vs PARK
BXRX vs PARK
Side-by-side comparison of Baudax Bio Inc. (BXRX) and Park Dental Partners Inc. (PARK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BXRX and PARK operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- PARK is the larger of the two at $97.3M, about 6.6x BXRX ($14.7M).
- PARK has hit the wire 6 times in the past 4 weeks while BXRX has been quiet.
- PARK has more recent analyst coverage (2 ratings vs 0 for BXRX).
- Company
- Baudax Bio Inc.
- Park Dental Partners Inc.
- Price
- $0.18+5.03%
- $20.87-0.71%
- Market cap
- $14.7M
- $97.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 2
Baudax Bio Inc.
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Latest BXRX
- SEC Form 8-K filed by Baudax Bio Inc.
- SEC Form 25-NSE filed by Baudax Bio Inc.
- SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)
- SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)
- Baudax Bio Inc. filed SEC Form 8-K: Other Events
- CORRECTION: BioCryst Pharmaceuticals Ticker is "BCRX
- BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness Activities
- SEC Form 424B3 filed by Baudax Bio Inc.
- SEC Form 10-Q filed by Baudax Bio Inc.
- SEC Form NT 10-Q filed by Baudax Bio Inc.
Latest PARK
- Officer Law Alan Siems gifted 80 shares, decreasing direct ownership by 0.04% to 180,961 units (SEC Form 4)
- SEC Form 10-Q filed by Park Dental Partners Inc.
- Park Dental Partners Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Park Dental Partners Announces Second Quarter 2026 Results
- Park Dental Partners Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Park Dental Partners, Inc. Announces Agreement to Acquire Village Family Dental Services Organization - Enters North Carolina Market
- Park Dental Partners Announces Dates for Second Quarter 2026 Earnings Release and Conference Call
- SEC Form 4 filed by Director Smith Philip Irving
- SEC Form 4 filed by CEO and Chairman Swenson Peter G
- SEC Form 4 filed by Officer Steele Christopher Eugene